Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Montine, T. J.
Right arrow Articles by Morrow, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montine, T. J.
Right arrow Articles by Morrow, J. D.
Neurology 1999;53:1495
© 1999 American Academy of Neurology


Articles

Elevated CSF prostaglandin E2 levels in patients with probable AD

T. J. Montine, MD, PhD, K. R. Sidell, BS, B. C. Crews, BS, W. R. Markesbery, MD, L. J. Marnett, PhD, L. J. Roberts, II, MD and J. D. Morrow, MD

From the Departments of Biochemistry (B.C. Crews and Dr. Marnett), Medicine (Drs. Roberts and Morrow), Pathology (Dr. Montine and K.R. Sidell), and Pharmacology (Drs. Montine, Roberts, and Morrow), the A.B. Hancock Jr. Memorial Laboratory for Cancer Research (Dr. Marnett), Vanderbilt University Medical Center, Nashville, TN; and the Departments of Pathology and Neurology and the Sanders Brown Center on Aging (Dr. Markesbery), University of Kentucky Medical Center, Lexington, KY.

Address correspondence and reprint requests to Dr. Thomas J. Montine, Department of Pathology, Vanderbilt University Medical Center, C-3321A Medical Center North, Nashville, TN 37232.

OBJECTIVE: To determine CSF eicosanoid concentrations and brain cyclo-oxygenase activity in AD patients and age-matched control subjects.

BACKGROUND: Nonsteroidal anti-inflammatory drugs may benefit AD patients by inhibiting cyclo-oxygenases and thereby reducing prostaglandin (PG) production or oxidant stress in the CNS.

METHODS: CSF eicosanoid and F2-isoprostane (IsoP) levels were determined in seven probable AD patients and seven age-matched control subjects. Cyclo-oxygenase activity was determined in microsomes prepared from the hippocampus of 10 definite AD patients and 8 age-matched control subjects. All measurements were made using gas chromatography/mass spectrometry.

RESULTS: CSF concentrations of prostaglandin (PG) E2 were increased fivefold (p < 0.01) and 6-keto-PGF1{alpha} was decreased fourfold (p < 0.01) in probable AD patients. There was no change in total CSF eicosanoid concentration in probable AD patients. CSF F2-IsoP, a quantitative marker of lipid peroxidation in vivo, was increased in probable AD patients (p < 0.05). Cyclo-oxygenase activity in the hippocampus from definite AD patients was not different from age-matched control subjects.

CONCLUSIONS: These data suggest that cyclo-oxygenase activity may not contribute significantly to CNS oxidative damage in AD. Increased CSF PGE2 concentration in probable AD patients suggest that cyclo-oxygenase inhibitors may benefit AD patients by limiting PG production.

Key words: CSF—AD—Prostaglandins—Cyclo-oxygenase.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
T. Hoshino, T. Namba, M. Takehara, T. Nakaya, Y. Sugimoto, W. Araki, S. Narumiya, T. Suzuki, and T. Mizushima
Prostaglandin E2 Stimulates the Production of Amyloid-{beta} Peptides through Internalization of the EP4 Receptor
J. Biol. Chem., July 3, 2009; 284(27): 18493 - 18502.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
L. A. Kotilinek, M. A. Westerman, Q. Wang, K. Panizzon, G. P. Lim, A. Simonyi, S. Lesne, A. Falinska, L. H. Younkin, S. G. Younkin, et al.
Cyclooxygenase-2 inhibition improves amyloid-{beta}-mediated suppression of memory and synaptic plasticity
Brain, March 1, 2008; 131(3): 651 - 664.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Hoshino, T. Nakaya, T. Homan, K.-i. Tanaka, Y. Sugimoto, W. Araki, M. Narita, S. Narumiya, T. Suzuki, and T. Mizushima
Involvement of Prostaglandin E2 in Production of Amyloid-beta Peptides Both in Vitro and in Vivo
J. Biol. Chem., November 9, 2007; 282(45): 32676 - 32688.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
M Combrinck, J Williams, M A De Berardinis, D Warden, M Puopolo, A D Smith, and L Minghetti
Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 85 - 88.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Coll. Nutr.Home page
B. Kumar, P. Nahreini, A. J. Hanson, C. Andreatta, J. E. Prasad, and K. N. Prasad
Selenomethionine Prevents Degeneration Induced by Overexpression of Wild-Type Human {alpha}-Synuclein during Differentiation of Neuroblastoma Cells
J. Am. Coll. Nutr., December 1, 2005; 24(6): 516 - 523.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
X. Liang, Q. Wang, T. Hand, L. Wu, R. M. Breyer, T. J. Montine, and K. Andreasson
Deletion of the Prostaglandin E2 EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease
J. Neurosci., November 2, 2005; 25(44): 10180 - 10187.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
M. T. Heneka, M. Sastre, L. Dumitrescu-Ozimek, A. Hanke, I. Dewachter, C. Kuiperi, K. O'Banion, T. Klockgether, F. Van Leuven, and G. E. Landreth
Acute treatment with the PPAR{gamma} agonist pioglitazone and ibuprofen reduces glial inflammation and A{beta}1-42 levels in APPV717I transgenic mice
Brain, June 1, 2005; 128(6): 1442 - 1453.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
T. J. Montine and J. D. Morrow
Fatty Acid Oxidation in the Pathogenesis of Alzheimer's Disease
Am. J. Pathol., May 1, 2005; 166(5): 1283 - 1289.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
F.-S. Shie, R. M. Breyer, and T. J. Montine
Microglia Lacking E Prostanoid Receptor Subtype 2 Have Enhanced A{beta} Phagocytosis yet Lack A{beta}-Activated Neurotoxicity
Am. J. Pathol., April 1, 2005; 166(4): 1163 - 1172.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Qin, L. Ho, P. N. Pompl, Y. Peng, Z. Zhao, Z. Xiang, N. K. Robakis, J. Shioi, J. Suh, and G. M. Pasinetti
Cyclooxygenase (COX)-2 and COX-1 Potentiate {beta}-Amyloid Peptide Generation through Mechanisms That Involve {gamma}-Secretase Activity
J. Biol. Chem., December 19, 2003; 278(51): 50970 - 50977.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
C. M. Clark and J. H.T. Karlawish
Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies
Ann Intern Med, March 4, 2003; 138(5): 400 - 410.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
L. Minghetti, F. Cardone, A. Greco, M. Puopolo, G. Levi, A. J.E. Green, R. Knight, and M. Pocchiari
Increased CSF levels of prostaglandin E2 in variant Creutzfeldt-Jakob disease
Neurology, January 8, 2002; 58(1): 127 - 129.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
L. Ho, J. D. Luterman, P. S. Aisen, G. M. Pasinetti, T. J. Montine, and J. D. Morrow
Elevated CSF prostaglandin E2 levels in patients with probable AD
Neurology, July 25, 2000; 55(2): 323 - 323.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by AAN Enterprises, Inc.